COPD
Chronic obstructive pulmonary disease or COPD is a set of chronic inflammatory lung disease. The disease is contributed by Emphysema and chronic bronchitis. Emphysema is the condition in which the alveoli get destroyed and chronic bronchitis is the condition where inflammation of the lining of the bronchial tubes takes place. The main cause for COPD is exposure to irritating gases or particulate matter, mostly cigarette smoke. People who smoke even after having asthma or people who have long-term exposure to chemical fumes, vapours and dust in the workplace, fumes from burning fuel for cooking and heating in poorly ventilated homes are at risk of developing COPD. Rare cause for COPD is genetic disorder: alpha-1-antitrypsin deficiency. COPD symptoms don’t appear initially hence research in COPD diagnosis in enhancing as misdiagnosis can increase the risk of COPD in the person cause heart disease, lung cancer and so on.
- Signs and Symptoms
- Diagnosis
- Prognosis and Epidemiology
- Alpha-1-antitrypsin deficiency
- COPD pathophysiology and research
- Emphysema and Chronic bronchitis
Related Conference of COPD
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
COPD Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Cancer Immunology and Immunotherapy - European Immunology 2025 (Italy)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Diagnostic and Technological Novelty of Immunology - European Immunology 2025 (Italy)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Epidemiology - European Immunology 2025 (Italy)
- Immune System - European Immunology 2025 (Italy)
- Immunodeficiency - European Immunology 2025 (Italy)
- Immunogenetics - European Immunology 2025 (Italy)
- Immunoinformatics & Systems Immunology - European Immunology 2025 (Italy)
- Immunological Techniques - European Immunology 2025 (Italy)
- Immunology - European Immunology 2025 (Italy)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Immunotherapy - European Immunology 2025 (Italy)
- Immunotoxicology - European Immunology 2025 (Italy)
- Infectious Diseases - Antibiotics 2026 (UK)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Neuroimmunology - European Immunology 2025 (Italy)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Parasite Immunology - European Immunology 2025 (Italy)
- Pediatrics Immunology - European Immunology 2025 (Italy)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- Reproductive Immunology - European Immunology 2025 (Italy)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)
- Transplantation Immunology - European Immunology 2025 (Italy)
- Viral Immunology - European Immunology 2025 (Italy)